The Zacks Analyst Blog Highlights: C.H. Robinson Worldwide, Merrimack Pharmaceuticals, Eli Lilly, Sanofi and Gilead Sciences

Zacks

For Immediate Release

Chicago, IL – August 26, 2013 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the C.H. Robinson Worldwide, Inc. (CHRW-Free Report), Merrimack Pharmaceuticals, Inc. (MACK-Free Report), Eli Lilly and Company (LLY-Free Report), Sanofi (SNY-Free Report) and Gilead Sciences Inc. (GILD-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday’s Analyst Blog:

C.H. Robinson Upgraded to Neutral

On Aug 23, 2013, we upgraded third-party logistics company, C.H. Robinson Worldwide, Inc. (CHRW-Free Report), to Neutral from Underperform.

Why the Upgrade?

We believe that the company’s diverse customer base, advanced technology and service levels, and brand value will help in winning market share over the long term. The company will gain through investments in complementary businesses like ocean, air and customs.

Detailed Analysis

C.H. Robinson is considered to be among the first-in-class third-party logistics (3PL) companies given its consistent growth rate in the past few years. The demand for 3PL services is rapidly growing as shippers seek cost-effective one-stop solutions for their freight forwarding requirements. Given the company’s advanced technology and service capabilities, we believe it is poised to capture a significant share in the current freight transportation market.

The acquisition of Phoenix is expected to expand the company’s global footprint in forwarding services in both ocean and air transportation categories along with custom brokerage. The company also acquired Poland-based freight forwarder – Apreo Logistics S.A – that mostly compliments its trucking business with dry van, temperature controlled as well as liquid and dry bulk capabilities. The acquisitions are expected to expose C.H. Robinson to higher growth markets.

C.H. Robinson continues to have a strong balance sheet with significant liquidity. The company also remains focused on increasing shareholders’ wealth by regular payments of dividends and share repurchases. We believe that increased returns strengthen shareholders’ confidence in the company.

Nevertheless, we prefer to stay on the sidelines as a competitive freight market, declining truckload market share and limited margin expansion opportunities pose as near-term headwinds.

Further, the higher personnel expenses given the rise in headcount and the increased integration cost associated with the Phoenix acquisition will hinder the company’s growth. Hence, the company is expected to perform at par with the broader industry and we advise investors to hold on to the stock.

C. H. Robinson currently carries a Zacks Rank #4 (Sell).

Merrimack Study Data Published

Merrimack Pharmaceuticals, Inc.’s (MACK-Free Report) recently announced the publication of a paper on its phase II study on its oncology candidate, MM-398, in the British Journal of Cancer.

MM-398 is currently in phase III development for the second-line treatment of pancreatic cancer patients, whose disease has progressed after being treated with Eli Lilly and Company’s (LLY-Free Report) Gemzar (gemcitabine). Merrimack expects to complete patient enrollment in the third quarter of 2013 and to report top-line results in fourth-quarter 2013 or first-quarter 2014 for this phase III study.

MM-398 was granted orphan drug designation by the European Medicines Agency (:EMA) and the U.S. Food and Drug Administration (:FDA) in 2011, for the treatment of pancreatic cancer. MM-398 is being studied in several phase I and phase II studies for cancer indications other than pancreatic cancer.

The company has an assignment, sublicense and collaboration agreement with PharmaEngine, Inc. Under the agreement, Merrimack reacquired the rights to MM-398 in Europe and certain other countries. Merrimack made an upfront payment of $10 million to PharmaEngine and will be making milestone payments.

Merrimack also has a license and collaboration agreement with Sanofi (SNY-Free Report) for the development of another oncology candidate, MM-121. MM-121 is being evaluated for multiple cancer indications including breast cancer (phase II).

We note that Merrimack has another oncology candidate, MM-111, in its pipeline. Last month, the company advanced MM-111 into phase II development for the treatment of advanced gastric, esophageal and gastroesophageal junction (:GEJ) cancer.

Merrimack currently carries a Zacks Rank #3 (Hold). At present, companies like Gilead Sciences Inc. (GILD-Free Report) look well-positioned with a Zacks Rank #1 (Strong Buy).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on CHRW - FREE

Get the full Report on MACK - FREE

Get the full Report on LLY - FREE

Get the full Report on SNY - FREE

Get the full Report on GILD - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

 

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Read the analyst report on CHRW

Read the analyst report on MACK

Read the analyst report on LLY

Read the analyst report on SNY

Read the analyst report on GILD

Zacks Investment Research



More From Zacks.com
View Comments (0)